Here, we introduce the OVV-Drive-IOTM approach, which involves using an oncolytic virus to express the highly immunogenic endogenous antigen NY-ESO-1, thereby constructing an oncolytic virus vaccine (OVV) to enhance anti-tumor immune activation. This evidence concerns the gene CTAG1B and neoplasm.